Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for pre-treated metastatic colorectal cancer harboring wild-type KRAS.

MLA

Shitara, Kohei, et al. “Phase II Study of Combination Chemotherapy with Biweekly Cetuximab and Irinotecan for Pre-Treated Metastatic Colorectal Cancer Harboring Wild-Type KRAS.” Japanese Journal of Clinical Oncology, vol. 40, no. 7, July 2010, pp. 699–701. EBSCOhost, https://doi.org/10.1093/jjco/hyq026.

APA

Shitara, K., Yokota, T., Takahari, D., Shibata, T., Ura, T., Komatsu, Y., Yuki, S., Yoshida, M., Takiuchi, H., Utsunomiya, S., Yatabe, Y., & Muro, K. (2010). Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for pre-treated metastatic colorectal cancer harboring wild-type KRAS. Japanese Journal of Clinical Oncology, 40(7), 699–701. https://doi.org/10.1093/jjco/hyq026

Chicago

Shitara, Kohei, Tomoya Yokota, Daisuke Takahari, Takashi Shibata, Takashi Ura, Yoshito Komatsu, Satoshi Yuki, et al. 2010. “Phase II Study of Combination Chemotherapy with Biweekly Cetuximab and Irinotecan for Pre-Treated Metastatic Colorectal Cancer Harboring Wild-Type KRAS.” Japanese Journal of Clinical Oncology 40 (7): 699–701. doi:10.1093/jjco/hyq026.